Adare Pharma Solutions and Laxxon Medical have initiated a collaboration to explore the application of 3D printing technology in pharmaceutical manufacturing. This partnership will leverage Adare’s Pessano facility in Milan to produce advanced oral dosage forms, utilizing Laxxon’s Screen-Printed Innovative Drug (SPID®) Technology.
The SPID® Technology, licensed from Exentis Group, represents a significant innovation in pharmaceutical design, allowing the creation of 3D-printed drugs with complex internal structures. These structures enable precise control over drug release profiles, improving bioavailability and drug delivery. One of the key advantages of this technology is its flexibility—tablets of varying sizes, from 200 microns to several centimeters, can be produced without modifying the production process. This scalability makes it suitable for both small-scale laboratory testing and larger clinical trial manufacturing.
By the end of 2024, the Pessano facility is expected to be fully equipped with a 3D printing system and bulk preparation mixer, facilitating the transition from experimental to clinical-scale drug production. This will allow the development of solutions such as taste masking, enhanced solubility, and formulations designed for easier swallowing, addressing common challenges in pharmaceutical development.
Image created by AI using DALL·E, generated via ChatGPT.
According to Tom Sellig, CEO of Adare, the collaboration will enhance their ability to serve markets in Europe, the U.S., and Asia by providing innovative manufacturing techniques. Helmut Kerschbaumer, CEO of Laxxon Medical, emphasized the significance of this collaboration in advancing global pharmaceutical technology.
Additionally, a second 3D printing system is planned for installation at Adare’s Vandalia, Ohio facility by the end of 2024, further expanding their capabilities in the U.S. and European markets. This partnership offers new possibilities for the development and production of complex drug formulations, reflecting a broader trend towards innovation in pharmaceutical manufacturing.
Stay informed on the latest industry trends following us on LinkedIn.
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.